New Tallahassee dispensary opening draws investor focus
Trulieve Cannabis (CNSX:TRUL) is drawing attention after announcing a new medical cannabis dispensary in Tallahassee, Florida, an expansion that broadens its retail footprint and branded product lineup in the state.
See our latest analysis for Trulieve Cannabis.
The new Tallahassee opening comes as Trulieve’s share price has a CA$13.0 latest close, with a 30 day share price return of 78.08% and a 1 year total shareholder return of 121.84%, suggesting momentum has recently picked up after mixed longer term results.
If you are looking beyond cannabis to see what else is moving in high growth themes, this is a good moment to check out 73 profitable AI stocks that aren’t just burning cash
With Trulieve trading at CA$13.00, at a substantial discount to both analyst targets and certain intrinsic value estimates despite recent strong returns, investors may wonder whether this represents a new entry point or if the market has already incorporated future growth into the price.
Most Popular Narrative: 36.1% Undervalued
With Trulieve’s fair value in the most followed narrative at CA$20.36 versus a CA$13.00 last close, the valuation work behind that gap is what really stands out.
The company’s successful expansion of branded product lines, such as Modern Flower, Roll One, and new THC beverage offerings, both through proprietary development and partnerships, is expected to strengthen brand equity, boost customer loyalty, and support recurring revenues and higher margins in a market that is increasingly valuing differentiated products.
Want to see what sits beneath that confidence in margins and brand strength? The narrative leans on measured revenue growth, improving profitability and a very ambitious future earnings multiple.
Result: Fair Value of CA$20.36 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, the story could change if cannabis reform stalls or Florida conditions worsen, given Trulieve’s regulatory dependence and heavy exposure to that single state.
Find out about the key risks to this Trulieve Cannabis narrative.
Next Steps
Curious whether the optimism or the caution in this story feels more compelling to you? Act while the numbers and narratives are fresh, and weigh both sides with the 1 key reward and 1 important warning sign.
Looking for more investment ideas?
Do not stop with just one stock when you can quickly scan other opportunities that might suit your goals and risk comfort using the Simply Wall St Screener.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Trulieve Cannabis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com